Abstracts tagged "Immunotherapy"

Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Nicholas Meti¹, Khashayar Esfahani^1,2, Ines Colmegna^1,3, Marvin J. Fritzler⁴, Nathalie A. Johnson^1,5, Ciriaco Piccirillo^1,6, Wilson H. Miller Jr.^1,2 and Marie Hudson^1,7, ¹Department of Medicine, McGill University, Montreal, QC, Canada, ²Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, ³Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, ⁶Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Vibeke Strand¹, M. Elaine Husni², Jenny Griffith³, Yan Song⁴, Rakesh Singh⁵, Jing Zhao⁶ and Keith A. Betts⁷, ¹Stanford University, Palo Alto, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Analysis Group Inc, Boston, MA, ⁷Analysis Group, Inc., Los Angeles, CA
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Daniela Rossi¹, Irene Cecchi², Massimo Radin³, Elena Rubini⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…
Abstract Number: 2095 • 2018 ACR/ARHP Annual Meeting
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Michelle Huang¹, Ariel Stock² and Chaim Putterman³, ¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Despite the many lupus patients affected by neuropsychiatric signs and symptoms, the pathogenesis of neuropsychiatric disease in SLE remains unclear. MRL-lpr/lpr mice, a classic…
Abstract Number: 2349 • 2018 ACR/ARHP Annual Meeting
“I Was Prepared for the Other Side Effects; I Wasn’t Prepared for This One.”: A Qualitative Study of the Patients’ Experience of Inflammatory Arthritis Due to Immune Checkpoint Inhibitor Therapy for Cancer
Laura C. Cappelli¹, Suzanne Grieb², Ana-Maria Orbai³, Ami A. Shah¹ and Clifton O. Bingham III⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients treated for cancer with immune checkpoint inhibitors (ICI) can develop a variety of adverse events. Inflammatory arthritis (IA) is an increasingly recognized event…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Pankti Reid¹ and Reem Jan², ¹Internal Medicine, rheumatology, University of Chicago, Chicago, IL, ²Medicine, Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…
Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
Abstract Number: 350 • 2018 ACR/ARHP Annual Meeting
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
Pankti Reid¹, Tara Chongsuwat², Anisha Dua³ and Jason Luke⁴, ¹Internal Medicine, rheumatology, University of Chicago, Chicago, IL, ²Oncology Research Coordinator, University of Chicago, Chicago, IL, ³Medicine, University of Chicago, Chicago, IL, ⁴Hematology Oncology, University of Chicago, Chicago, IL
Background/Purpose: Checkpoint immunotherapy has become the standard of care in treating advanced melanoma. These medications have been associated with immune-related adverse events (irAEs). Accurate methods…
Abstract Number: 352 • 2018 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
Cassandra Calabrese¹, Elizabeth Kirchner¹ and Leonard H. Calabrese², ¹Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Rheumatic immune related adverse events (irAEs) from checkpoint inhibitor (ICI) therapy remain poorly understood. In our early experience with rheumatic irAEs we encountered patients…
Abstract Number: 353 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
José Luis Martín-Varillas¹, Íñigo González-Mazón¹, Belén Atienza-Mateo¹, Marina Delagado Ruiz², Isabel Bernat Piña², Diana Prieto Peña³, Monica Calderón Goercke³, Lara Sánchez-Bilbao¹, Eva Peña Sainz-Pardo², Almudena García Castaño², Miguel Angel González-Gay² and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Immune checkpoint blockade therapy (ICTB) has shown remarkable benefit in different cancer types. Blockade of intrinsic down-regulators of immunity increases the activity of the…
Abstract Number: 354 • 2018 ACR/ARHP Annual Meeting
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Mazen Nasrallah¹, Meghan Mooradian², Eli Miloslavsky³, Justine Cohen², Justin Gainor², Donald Lawrence², Kerry Reynolds², Minna Kohler⁴, Ryan Sullivan² and Sara Schoenfeld¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have led to improved outcomes in multiple cancers, but they are associated with immune-related adverse events (irAEs), including inflammatory arthritis.…
Abstract Number: 356 • 2018 ACR/ARHP Annual Meeting
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Rachel Romero¹, Todd Schwartz², Shruti Saxena Beem¹ and Rumey Ishizawar³, ¹Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting CTLA-4, such as ipilimumab (anti-CTLA4), or PD-1/PD-L1, such as nivolumab and pembrolizumab are increasingly utilized in a wide variety…
Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abhishikta Dey^1,2, Nicholas Manolios^3,4, Georgina Long^4,5,6, Richard Kefford^3,4,5,7 and Leslie Schrieber^8,9, ¹Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, ²Royal North Shore Hospital, North Sydney, Australia, ³Westmead Hospital, Sydney, Australia, ⁴University of Sydney, Sydney, Australia, ⁵Melanoma Institute Australia, North Sydney, Australia, ⁶Royal North Shore Hospital, St Leonards, Australia, ⁷Macquarie University Hospital, Sydney, Australia, ⁸Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁹Northern Clinical School, University of Sydney, Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
Abstract Number: 1156 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data
Cassandra Calabrese¹, Elizabeth Kirchner¹, Apostolos Kontzias¹, Laura Wood², Brian Rini², Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The new and emerging field of immune related adverse events (irAEs) from cancer immunotherapies presents many unanswered questions. The spectrum of irAEs is broad…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].